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We recently demonstrated that reducing IGF-1 receptor (IGF-1R)
numbers in the endothelium enhances nitric oxide (NO) bio-
availability and endothelial cell insulin sensitivity. In the present
report, we aimed to examine the effect of increasing IGF-1R on
endothelial cell function and repair. To examine the effect of in-
creasing IGF-1R in the endothelium, we generated mice over-
expressing human IGF-1R in the endothelium (human IGF-1R
endothelium-overexpressing mice [hIGFREO]) under direction of
the Tie2 promoter enhancer. hIGFREO aorta had reduced basal
NO bioavailability (percent constriction to NG-monomethyl-L-
arginine [mean (SEM) wild type 106% (30%); hIGFREO 48%
(10%)]; P , 0.05). Endothelial cells from hIGFREO had reduced
insulin-stimulated endothelial NO synthase activation (mean
[SEM] wild type 170% [25%], hIGFREO 58% [3%]; P = 0.04) and
insulin-stimulated NO release (mean [SEM] wild type 4,500 AU
[1,000], hIGFREO 1,500 AU [700]; P , 0.05). hIGFREO mice had
enhanced endothelium regeneration after denuding arterial injury
(mean [SEM] percent recovered area, wild type 57% [2%], hIG-
FREO 47% [5%]; P, 0.05) and enhanced endothelial cell migration
in vitro. The IGF-1R, although reducing NO bioavailability, enhan-
ces in situ endothelium regeneration. Manipulating IGF-1R in the
endothelium may be a useful strategy to treat disorders of vascular
growth and repair. Diabetes 61:2359–2368, 2012
Insulin-resistant type 2 diabetes characterized byperturbation of the insulin/IGF-1 system is a multi-system disorder of nutrient homeostasis, cell growth,and tissue repair (1). As a result, type 2 diabetes is a
major risk factor for the development of a range of disorders
of human health, including occlusive coronary artery disease
(2), peripheral vascular disease (3), stroke (4), chronic
vascular ulcers (5), proliferative retinopathy (6), and ne-
phropathy (7). A key hallmark of these pathologies is
endothelial cell dysfunction characterized by a reduction in
bioavailability of the signaling radical nitric oxide (NO). In
the endothelium, insulin binding to its tyrosine kinase re-
ceptor stimulates release of NO (8). Insulin resistance at
a whole-body level (9,10) and speciﬁc to the endothelium
(11) leads to reduced bioavailability of NO, indicative of a
critical role for insulin in regulating NO bioavailability.
The insulin receptor (IR) and IGF-1 receptor (IGF-1R)
are structurally similar—both composed of two extracellu-
lar a and two transmembrane b subunits linked by disulﬁde
bonds (12). As a result, IGF-1R and IR can heterodimerize
to form insulin-resistant hybrid receptors composed of one
IGF-1R-ab complex and one IR-ab subunit complex (13,14).
We recently demonstrated that reducing IGF-1R (by re-
ducing the number of hybrid receptors) enhances insulin
sensitivity and NO bioavailability in the endothelium (15).
To examine the effect of increasing IGF-1R speciﬁcally in
the endothelium on NO bioavailability, endothelial repair,
and metabolic homeostasis, we generated a transgenic mouse
with targeted overexpression of the human IGF-1R in the
endothelium (hIGFREO).
RESEARCH DESIGN AND METHODS
Generation of hIGFREO mice. To overcome the limitations of random and
multiple copy insertion sites seen in standard transgenics, we used the hy-
poxanthine phosphoribosyl transferase (Hprt) targeting system (Genoway; see
ref. 16) to generate genetically modiﬁed embryonic stem (ES) cells. This ap-
proach uses homologous recombination to target a single copy of a transgene (in
this case, the human IGF-1r), driven by a promoter (in this case, the Tie2 pro-
moter), into the Hprt locus on the X chromosome. The model was developed
with E15Tg2a (E14) cells derived from the strain 129P2/OiaHsd (12901a). In E14
cells, 35 kb of theHprt gene encompassing the 59 untranslated region up to intron
2 is deleted. The Hprt gene encodes a constitutively expressed housekeeping
enzyme involved in the synthesis of purines from the degradation products of
nucleotide bases (salvage pathway). Cells normally synthesize purines by the
salvage and de novo pathways. In Hprt-deleted cell lines, only the de novo
pathway is functional, enabling the cells to grow in classical medium. However,
in the presence of the aminopterin drug, the de novo pathway is blocked. As
a result, Hprt-deleted cells die in hypoxanthine-aminopterin-thymidine (HAT)
media (containing HAT substrates). The targeted insertion of a transgenic cas-
sette in E14 ES cells with a functional Hprt gene rescues these cells, which can
then be selected using HAT media to identify ES cells showing the correct
targeting event. ES cells with the correct insertion can be selected by virtue of
their expression of Hprt and their ability to grow in HAT medium. Numerous
studies have shown that the functional properties of the Hprt locus protect
transgenic constructs inserted in this region against gene silencing and posi-
tional or methylation effects. Furthermore, tissue-speciﬁc promoters including
Tie2 (17) inserted into the Hprt locus maintain their expression properties.
Vector construction. Endothelium-speciﬁc transgene expression was ach-
ieved using the mouse Tie2 promoter and intronic enhancer as previously
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described (11,18). To reduce the size of the transgene, the minimal enhancer
sequence (core enhancer) was inserted into the ﬁnal construct. This sequence
has been shown to confer a uniform and high level of expression of LacZ
reporter gene in endothelial cells in vivo (17). The targeting vector was ob-
tained by inserting human IGF-1R cDNA (a gift from Dr. R. Baserga, Jefferson
University) (19) into the pHHNS plasmid (11,18), comprising the murine Tie2
promoter, LacZ cDNA, and SV40 polyA signal and a 10-kb intronic enhancer
from the murine Tie2. The ﬁnal transgenic vector (Fig. 1A), consisting of Tie2
promoter, human IGF-1R cDNA, SV40 polyadenylation site, and core en-
hancer, was then inserted into an Hprt targeting vector using standard
cloning. The ﬁnal targeting vector had the following features: 1) homology
arms isogenic with E14 ES cells favoring homologous recombination;
2) symmetrical homology arms (59 short arms: 3.8 kb, 39 long arm: 3.7 kb);
3) transgenic cassette expressing the human IGF-1R cDNA under control of
the short form of the Tie2 promoter; and 4) wild-type Hprt sequences to
reconstitute the Hprt gene in the E14 ES cells. In ES cells, this process was
highly successful, with three clones selected for blastocyst injection. The
59 and 39 targeting events were unambiguously conﬁrmed by Southern blot
analysis. These three ES clones were expanded and recombinant ES cells
injected into C57BL/6J-derived blastocysts that were then implanted into the
uteri of recipient females.
Breeding of chimeras and generation of F1 mice heterozygous for the
human IGF-1R in the endothelium. Seven highly chimeric males generated
by blastocyst injection of ES clones were mated with two wild-type C57BL/6J
female mice to examine whether the recombinant ES cells contributed to the
germ layer. To assess whether ES cells have contributed to the germ layer of
chimeras, mouse coat color markers were used. The ES cells used to develop
the model were originally derived from a 129 strain of mice that have an agouti
coat color. This marker is dominant over the black coat of C57BL/6 mice.
Therefore, mating of the chimeras with C57BL/6J mice should yield agouti-
colored pups when the ES cells have contributed to the germ layer. Eight out of
20 agouti F1 females were genotyped by Southern blot. Southern blot validated
the correct heterozygous status of eight tested F1 females by detecting the 7.9-kb–
sized AvrII fragment of the C57BL/6J Hprt wild-type allele and the 9.8-kb–sized
AvrII fragment of the reconstituted Hprt allele (Fig. 1B).
Mice with endothelium-speciﬁc deletion of the IGF-1R. To generate
mice with endothelium-speciﬁc deﬁciency of the IGF-1R, we used mice
carrying a ﬂoxed IGF-1R allele (IGF-1RLox) as previously described (15) and
mice expressing the cre-recombinase under control of the Tie2 promoter
(Tie2 cre; The Jackson Laboratory, Bar Harbor, ME). Male heterozygous
Tie2-cre/IGF-1RLox mice were compared with age-matched littermate
controls.
Breeding and maintenance of gene-modiﬁed mice. hIGFREO mice and
mice with endothelium-speciﬁc haploinsufﬁciency of the IGF-1R (ECIGF-1R+/2)
were bred onto a C57BL/6J background to at least 12 generations. Mice were
housed in a conventional animal facility with a 12-h light/dark cycle. Geno-
typing was performed using ear notch DNA (Fig. 1C). Male mice aged 3–5
months were used in all experiments, which were conducted in accordance
with accepted standards of humane animal care under United Kingdom Home
Ofﬁce Project license number 40/3523.
FIG. 1. Generation of transgenic hIGFREO mice using the Hprt targeting strategy. A: Construction of the Hprt targeting vector, homologous
recombination in ES cells at the Hprt locus, blastocyst injection of recombined Hprt ES cell clones, and generation of chimeras. B: Southern blot
analysis of the F1 generation. The genomic DNA of the eight F1-tested mice #01-08 was compared with wild-type DNA (E14, BL6). The AvrII-
digested DNAs were blotted on nylon membranes and hybridized with a 59 probe to validate the recombined Hprt allele in these animals. The
Southern blot validated the correct heterozygous status of eight tested F1 females by detecting the 7.9-kb–sized AvrII fragment of the recombined
Hprt allele. C: Genotyping of transgenic mice with endothelial cell–speciﬁc expression of the human IGF-1R. TG, transgenic; WT, wild type. (A
high-quality color representation of this ﬁgure is available in the online issue.)
IGF-1R, NITRIC OXIDE, AND INSULIN RESISTANCE
2360 DIABETES, VOL. 61, SEPTEMBER 2012 diabetes.diabetesjournals.org
Metabolic tests. Glucose, insulin, and IGF-1 tolerance tests were performed
by blood sampling after an intraperitoneal injection of glucose, human re-
combinant insulin, or IGF-1 as previously described (15,20,21). Glucose con-
centrations were determined in whole blood using a portable meter. Plasma
insulin and IGF-1 levels were determined by enzyme-linked immunoassay
(20,21).
Studies of vasomotor function in aortic rings. Vasomotor function was
assessed ex vivo in aortic rings as previously described (21).
FIG. 2. Growth curves and organ mass of hIGFREO mice. A: No difference in growth pattern of hIGFREO mice. B: No difference in organ weight of
hIGFREO mice. All experiments at least n = 6 mice per group. BW, body weight.
FIG. 3. Characterization of hIGFREO mice. A: Expression of human IGF-1R in organs from hIGFREO mice and wild-type littermate controls.
B: Expression of native (mouse) IGF-1R in organs from hIGFREOmice and wild-type littermate controls.C: No difference in murine IGF-1R expression
in endothelial cells (EC) from hIGFREOmice compared with wild type.D: Expression of human IGF-1R in endothelial cells from hIGFREOmice and no
expression in endothelial cells from wild-type mice or nonendothelial cells from hIGFREO mice. E: Vascular-endothelial-cadherin (Ve-cadherin) ex-
pression in endothelial cells from hIGFREOmice with no expression in nonendothelial cells. F: Expression of mouse IGF-1R protein in endothelial cells
from hIGFREO mice and wild-type littermates showing signiﬁcantly greater levels in hIGFREO. All experiments at least n = 6 mice per group.
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NO synthase activity. After activation, endothelial NO synthase (eNOS)
produces NO and L-citrulline in a stoichiometric reaction. The effect of insulin/
IGF-1 on eNOS activity in endothelial cells was determined by conversion of
[14C]-L-arginine to [14C]-L-citrulline (15,20).
Quantiﬁcation of eNOS, serine 1177-phosphorylated eNOS, serine-
phosphorylated Akt, neuronal NO synthase, IGF-1R, insulin receptor,
tyrosine-phosphorylated insulin receptor, and hybrid receptors. Protein
expression was quantiﬁed in endothelial cells (before and after 10-min exposure
to 150 nmol/L insulin or IGF-1) using Western blotting with b-actin as control
(15,20,21). Immunoprecipitation of protein for the quantiﬁcation of hybrid re-
ceptors and tyrosine-phosphorylated IR was performed as previously reported
(15), incubating equal amounts of protein lysates (100 mg) and 50 mL of protein
A-DynaBeads (Invitrogen) precoated with indicated anti-rabbit antibodies for
20 min. After three rounds of washing with PBS/0.01% Tween 20, the beads were
resuspended in 23 Laemmli loading buffer supplied with the NOVEX Gel
Electrophoresis system (Invitrogen). Aortic protein was separated by SDS-PAGE,
and blots were probed with a mouse anti–IGF-1R-a (for hybrid expression),
IR-b (C-19), and IGF-1R-b (C-20), antibodies for receptor expression (Santa Cruz
Biotechnology), Akt, phosphorylated Akt (pAkt) (21) (Cell Signaling Technology,
Beverley, MA), and neuronal NO synthase (nNOS; Transduction Laboratories,
Franklin Lakes, NJ). Tyrosine-phosphorylated IR expression was examined
in pulmonary endothelial cells (PECs) as we previously reported (15).
Cell lysis, immunoblotting, and immunoprecipitation. Primary cells were
lysed in extraction buffer containing (in mmol/L unless otherwise noted): 50
HEPES, 120 NaCl, 1 MgCl2, 1 CaCl2, 10 NaP2O7, 20 NaF, 1 EDTA, 10%
glycerol, 1% Nonidet P-40, 2 sodium orthovanadate, 0.5 mg/mL leupeptin, 0.2
phenylmethylsulfonyl ﬂuoride, and 0.5 mg/mL aprotinin. Cell extracts were
sonicated in an ice bath and centrifuged for 15 min before protein measurements
were carried out by BCA assay (Pierce) using the supernatant. Equal amounts of
cellular protein were resolved on NuPage 4–12% Bis-Tris gels (Invitrogen) and
transferred to polyvinylidene diﬂuoride membranes. Immunoblotting was carried
out with indicated primary antibodies. Blots were incubated with appro-
priate peroxidase-conjugated secondary antibodies and developed with en-
hanced chemiluminescence (Millipore). Fifty micrograms of total cell lysate was
used for immunoprecipitation with indicated antibodies: IR-b (C19; Santa Cruz
Biotechnology) and Protein A-DynaBeads (Invitrogen) for 20 min at room
temperature. Immune complexes were collected using magnetic ﬁeld, washed
extensively with PBS/0.02% Tween 20, solubilized in Laemmli sample buffer, and
analyzed as above. Immunoblots were scanned on a Kodak camera-scanner
Image Station 2000R, and bands were quantiﬁed using Kodak ID Image Analysis
software (Kodak).
Gene expression.mRNA was isolated using a commercial kit (Roche) and the
levels of IGF-1R, IR, nNOS, and eNOS mRNA quantiﬁed using real-time quanti-
tative PCR (9,15); a range of housekeeping genes were screened for validity and
stability prior to measurements (data not shown). Nonspeciﬁc primers and those
speciﬁc for human and mouse IGF-1R were designed and validated in human
umbilical vein endothelial cells and mouse pulmonary endothelial cells (PECs)
(Supplementary Table 1).
PEC isolation and culture. Primary PECs were isolated from murine lung as
we previously described (15).
Fluorescence-based measurement of NO. Insulin- and IGF-1–mediated
NO release was measured using 4-amino-5-methylamino-2-diﬂuoroﬂuorescein
(DAF-FM) ﬂuorescence (Invitrogen) as we recently described (15).
Femoral artery endothelial denuding arterial injury and en face micros-
copy. Femoral artery wire injury was performed as we previously reported
(10). Mice were anesthetized at 5 days after wire injury and 50 mL of 5% Evans
blue dye injected into the vena cava. The mice were perfused/ﬁxed with
formaldehyde before femoral arteries (injured and uninjured) were harvested.
The vessels were opened longitudinally. The areas stained and unstained in blue
were measured in the injured area 5 mm from the proximal suture and the
percentage areas calculated using ImagePro Plus 6.0 software (Media Cyber-
netics, Bethesda, MD).
Endothelial cell migration. PECs were suspended in supplemented basal
medium. Approximately 4 3 104 cells in 500 mL MV2 medium (PromoCell,
Heidelberg, Germany) were placed in the upper compartment of a Modiﬁed
Boyden chamber with a polycarbonate membrane containing 8 mm pores. The
lower compartment contained 750 mL MV2 and 50 ng/ml vascular endothelial
growth factor (VEGF165); negative control wells contained basal MV2 medium
(vehicle) alone. Wells were set up in triplicate and incubated in 5% CO2 at 37°C
for 24 h. Membranes were ﬁxed in 70% ethanol at 220°C for 1 h before
FIG. 4. Metabolic function in hIGFREO mice. Increasing endothelium IGF-1R has no effect on glucose tolerance or insulin sensitivity. A: Glucose
tolerance tests. B: Insulin tolerance tests. C: IGF-1 tolerance tests. D: Fasting insulin. E: Fasting IGF-1. All experiments at least n = 10 mice per
group. (Area under the curve [AUC] represents absolute change in glucose.)
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mechanical removal of cells adherent to the upper surface using a cotton
swab. Hematoxylin and eosin stains were then applied (30 s each) to mem-
branes that were then washed in water and mounted on glass slides. Migrant
PECs were counted in 10 high-power ﬁelds (3200 magniﬁcation, area of 7203
530 mm). Results expressed as mean cell number per high-power ﬁeld.
Endothelial progenitor cell isolation. Endothelial progenitor cells (EPC)
were isolated from bone marrow and spleen as we previously reported (10).
Statistics. Results are expressed as mean (SEM). Comparisons within groups
were made using paired Student t tests and between groups using unpaired
Student t tests or repeated-measures ANOVA, as appropriate; when repeated
t tests were performed, a Bonferroni correction was applied. A P value ,0.05
was considered statistically signiﬁcant.
RESULTS
Generation and characterization of transgenic hIGFREO
mice. We generated a novel hIGFREO mouse (Figs. 1–3).
hIGFREO mice were born with the same frequency as wild-
type mice. There was no difference in behavior, grooming,
growth (Fig. 2A), or organ weight (Fig. 2B). We deter-
mined the levels of human and native (mouse) IGF-1R
mRNA expression in organs with different proportions of
endothelial cells (lung, aorta, and spleen). Human IGF-1R
mRNA expression was approximately threefold higher
in lung than in aorta from hIGFREO; P , 0.01 (Fig. 3A).
In spleen, there was very little IGF-1R, commensurate
with proportionately fewer endothelial cells. Human
IGF-1R expression in hIGFREO mice tracked the pattern
for native IGF-1R seen in wild-type mice (Fig. 3B). There
was no difference in expression of mouse IGF-1R be-
tween hIGFREO and wild type (Fig. 3C). There was no
hIGF-1R mRNA detectable in endothelial cells from wild-
type mice or nonendothelial cells from hIGFREO mice
(Fig. 3D); nonendothelial cells did not express the
endothelial-speciﬁc marker vascular-endothelial-cadherin
in contrast to endothelial cells (Fig. 3E). Western blot anal-
ysis conﬁrmed that total IGF-1R protein levels were signiﬁ-
cantly increased in hIGFREO endothelial cells compared
with wild type (Fig. 3F).
hIGFREO mice have normal glucose homeostasis.
hIGFREO had similar responses to insulin, glucose, and
IGF-1 tolerance tests as wild-type mice (Fig. 4A–C). Fasting
glucose (4.4 [0.3] versus 4.5 [0.3] mmol/L; P = NS), insulin
(hIGFREO 2.0 [0.3] versus wild-type 2.1 [0.3] ng/ml; P = NS),
and IGF-1 (hIGFREO 474 [31] versus wild-type 471 [16] ng/ml;
P = NS) were similar in hIGFREO and wild-type mice
(Fig. 4D and E).
hIGFREO increases hybrid receptors but has no effect
on eNOS expression, aortic relaxation in response
to IGF-1, or eNOS activation in response to IGF-1.
There were no differences in endothelial cell or lung eNOS
mRNA (Fig. 5A). In keeping with our previous report (15),
FIG. 5. hIGFREO mice have similar eNOS mRNA in endothelial cells and lung tissue. hIGFREO mice have increased hybrid receptors, similar serine
1177-phosphorylated eNOS protein expression, and similar aortic relaxation and eNOS activation in response to IGF-1 as wild-type littermates.
A: No differences in endothelial cell or lung eNOS mRNA from hIGFREO mice compared with wild-type littermates. B: Increased hybrid receptors in
endothelial cells from hIGFREO mice. C: No differences in serine-phosphorylated eNOS protein concentration in endothelial cells from hIGFREO
mice. D: No difference in eNOS activation in response to IGF-1 in hIGFREO mice. E: Aortic relaxation responses in hIGFREO mice in response to
IGF-1. F: Aortic relaxation responses in wild-type littermates (all experiments at least n 5 6 mice per group).
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insulin-resistant hybrid receptors were increased in en-
dothelial cells from hIGFREO mice (Fig. 5B); there was
no difference in IR-b or tyrosine-phosphorylated IR-b ex-
pression between hIGFREO and wild-type littermates (Sup-
plementary Fig. 1). Basal serine 1177 eNOS phosphorylation
(Fig. 5C), eNOS activation (Fig. 5D), and aortic ring re-
laxation responses (Fig. 5E and F) in response to IGF-1
were no different when comparing hIGFREO mice and wild-
type mice. Insulin-mediated aortic relaxation in hIGFREO
mice was no different than wild-type mice (data not shown).
IGF-1–stimulated 1177 serine phosphorylation of eNOS was
similar in endothelial cells from hIGFREO and wild-type
mice (Supplementary Figs. 2 and 3).
hIGFREO mice have increased constrictor responses
to phenylephrine, reduced basal NO bioavailability,
and normal responses to acetylcholine and sodium
nitroprusside. There were no differences in aortic ring
relaxation responses to acetylcholine or SNP between
mice (Fig. 6A and B). In contrast to this, hIGFREO mice
had enhanced constrictor responses to phenylephrine (Fig.
6C), and consistent with reduced basal NO bioavailability,
a blunted constrictor response toNG-monomethyl-L-arginine
(L-NMMA) (Fig. 6D–F).
hIGFREO mice have similar arterial blood pressure as
wild-type littermates. Trained, semirestrained hIGFREO
mice had systolic blood pressure of 106.7 (3.0) mmHg
compared with wild-type littermates 105.8 (4.5) mmHg;
P = 0.8 (Fig. 7A).
hIGFREO mice have reduced insulin-stimulated eNOS
serine 1177 phosphorylation, reduced insulin-stimulated
eNOS activity, and reduced insulin-stimulated NO
production in endothelial cells. Insulin-mediated NO
release (Fig. 7B and C), eNOS activation (Fig. 7D), and
eNOS serine 1177 phosphorylation (Fig. 7E) were blunted
in hIGFREO endothelial cells compared with wild type.
hIGFREO mice have reduced neuronal NO synthase
protein expression in endothelial cells. Recent studies
provide compelling evidence for a role for nNOS-derived
NO in basal vascular tone (22). We therefore measured
nNOS mRNA and protein expression in endothelial cells
from wild-type and hIGFREO mice. There was no differ-
ence nNOS mRNA expression (data not shown), whereas
protein expression was reduced approximately twofold in
hIGFREO mice (Supplementary Fig. 4).
hIGFREOmice have enhanced endothelial cell migration
and accelerated endothelial regeneration after arterial
injury. Endothelium regeneration after wire injury (Fig. 8A)
was signiﬁcantly enhanced in hIGFREO mice compared
with wild-type mice (percent recovered area wild type 57%
[2%] versus hIGFREO 47% [5%]; P , 0.05). Consistent with
enhanced in situ endothelium regeneration, migration to
control and VEGF was substantially enhanced in endothe-
lial cells from hIGFREO mice (Fig. 8B). To further examine
the role of the IGF-1R in endothelial regeneration after de-
nuding arterial injury, we performed complementary wire
injury experiments in ECIGF-1R+/2 mice and assessed
FIG. 6. Endothelial function in hIGFREO mice. A: Acetylcholine relaxation responses are similar in hIGFREO mice compared with wild-type lit-
termates. B: Single nucleotide polymorphism (SNP) relaxation responses are similar in hIGFREO mice compared with wild-type littermates.
C: Phenylephrine constriction curves demonstrating enhanced constriction to phenylephrine in hIGFREO mice. D: Constriction to L-NMMA in wild-
type mice. E: Constriction to L-NMMA in hIGFREO mice indicative of reduced basal NO bioavailability compared with wild-type mice. F: Maximal
constriction to L-NMMA in hIGFREO mice and wild-type littermates. All experiments at least n 5 6 mice per group. *P < 0.05.
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regeneration. Consistent with our ﬁndings in hIGFREO
mice, ECIGF-1R+/2 mice had blunted endothelium regen-
eration when compared with wild-type littermates (percent
recovered at 5 days, ECIGF-1R+/2 26% (1%) versus wild-type
42% (1%); P , 0.01) (Fig. 8C). We examined the expression
of hIGF-1R in spleen and bone marrow-derived EPC, and
hIGF-1R was expressed in EPC from hIGFREO but not wild
type (Supplementary Fig. 5).
DISCUSSION
In this study, we describe the phenotype of a novel trans-
genic mouse with endothelium-targeted expression of the
human IGF-1R generated to investigate the role of the IGF-
1R in regulating endothelial cell function. The major ﬁndings
of this study are as follows: 1) endothelial-speciﬁc IGF-1R
overexpression leads to an increase in total IGF-1R mRNA
and protein in hIGFREO mice compared with wild-type
littermates; 2) endothelial IGF-1R overexpression is asso-
ciated with an increase in vasoconstrictor responsiveness
to phenylephrine, reduced basal NO release, and reduced
nNOS expression; 3) the IGF-1R is a potent negative reg-
ulator of insulin-mediated NO release; and 4) despite this
reduced NO bioavailability, endothelial IGF-1R overex-
pression leads to enhanced endothelium regeneration after
denuding wire injury.
The IGF-1R is a negative regulator of insulin sensi-
tivity and NO bioavailability in the endothelium. We
recently demonstrated that global haploinsufﬁciency of
the IGF-1R enhances whole-body insulin sensitivity and
insulin-mediated NO production (15) and knocking down
IGF-1R in human endothelial cells enhanced basal and
insulin-stimulated serine-phosphorylated eNOS. In mice
with endothelium-speciﬁc knockdown of the IGF-1R, we
conﬁrmed a gene-dose response effect on basal NO bio-
availability. Moreover, by crossing IGF-1R haploinsufﬁcient
mice with IR-haploinsufﬁcient mice (IR+/2), we were able to
restore insulin-mediated NO release in IR+/2 mice. We also
showed that reducing IGF-1R density altered IGF-1R–IR
stoichiometry in favor of IR holoreceptors with a relative
reduction in insulin-resistant hybrid receptors.
In the present report, we demonstrate that increasing
IGF-1R numbers speciﬁcally in the endothelium has no ef-
fect on the response to systemic insulin, IGF-1, or glucose.
Despite having no effect on whole-body glucose homeosta-
sis, IGF-1R overexpression led to reduced insulin-stimulated
eNOS serine phosphorylation, eNOS activation, and NO
generation. Overexpression of the IGF-1R also reduced
basal NO bioavailability. Reduced NO has been shown to
promote the development of atherosclerosis (23,24). Serine
phosphorylation increases eNOS calcium sensitivity and
augments NO biosynthesis and release (25); consistent with
FIG. 7. Systolic blood pressure, insulin-stimulated eNOS phosphorylation, eNOS activation, and NO production in endothelial cells from hIGFREO
mice. A: Systolic blood pressure is similar in hIGFREO mice and wild-type littermates. B: Insulin-mediated NO release in endothelial cells from
wild-type mice and hIGFREO mice showing blunted responses in hIGFREO mice. C: Representative time-series graph for change of DAF-FM
ﬂuorescence (Invitrogen) in PECs in response to insulin (100 nmol/L). D: eNOS activity in response to insulin in endothelial cells from hIGFREO
and wild-type mice showing blunted responses in hIGFREO mice. E: Serine 1177 phosphorylation of eNOS in endothelial cells in response to insulin
is blunted in hIGFREO mice compared with wild-type littermate mice. All experiments at least n 5 6 mice per group. (A high-quality color rep-
resentation of this ﬁgure is available in the online issue.)
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this, eNOS phosphorylation status has been shown to play
an important and favorable role in a range of pathological
situations reminiscent of human vascular disease (26,27).
Our dataset demonstrates that a relative increase in IGF-1R
in relation to IR, which is a hallmark of type 2 diabetes
(28,29), has an unfavorable impact on NO bioavailability.
The IGF-1R has pathway-selective effects on eNOS
activation. eNOS can be activated by a range of different
stimuli. Fluid shear stress and growth factors such as in-
sulin activate eNOS via phosphatidylinositol 3-kinase and
Akt/protein kinase B activation in what is often described
as a calcium-independent fashion (25). Secondly, different
agonists (such as acetylcholine) activate eNOS by stimu-
lating a rise in intracellular calcium, described as calcium-
dependent eNOS activation (30). In the present report, we
have shown that the IGF-1R selectively inhibits insulin-
mediated eNOS activation with preservation of acetylcho-
line responses. Interestingly, hIGFREO mice had a relative
reduction in endothelial cell expression of nNOS, possibly
contributing to reduced basal NO bioavailability.
hIGFREO, glucose homeostasis, growth, and metabo-
lism. Endothelial cell-speciﬁc overexpression of the IGF-
1R had no effect on growth, whole body, or organ weight.
In contrast to a recent report (31), the endothelial cell in-
sulin resistance demonstrated in the present report had no
effect on whole-body glucose uptake. The mechanisms
underlying the difference between mice with endothelium-
speciﬁc deletion of IR substrate-2 described by Kubota
et al. (31) and hIGFREO mice are unclear. It may be that
insulin resistance in the endothelium due to perturbation
of insulin signaling at its most proximal signaling node
(i.e., the IR), as seen in this report, our previous study (11),
and that of Vicent et al. (32), does not affect insulin sensi-
tivity in skeletal muscle. These data highlight the complexity
of communication between different cell types involved in
insulin signaling.
The IGF-1R enhances endothelium regeneration. It is
now a well-accepted paradigm that cardiovascular risk
factors lead to damage/death of resident endothelial cells,
and endogenous repair mechanisms are activated to repair
FIG. 8. hIGFREO mice have enhanced endothelial cell migration in vitro and accelerated endothelial repair after denuding femoral artery wire
injury. A: Endothelial regeneration in hIGFREO mice and wild-type littermates after wire injury showing enhanced endothelial regeneration in
hIGFREO mice. B: Migration to VEGF and control media is enhanced in PECs from hIGFREO mice. C: Endothelial regeneration in wild-type and
ECIGF-1R+/2 mice after wire injury showing blunted regeneration in ECIGF-1R+/2 mice. All experiments at least n = 6 mice per group. HPF, high-
power ﬁeld. (A high-quality color representation of this ﬁgure is available in the online issue.)
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the damage (for review, see Ref. 33). Intriguingly and de-
spite reduced NO bioavailability, overexpression of the
human IGF-1R in the endothelium accelerated repair of the
endothelium after wire injury. Recent data demonstrate
that repair of denuded endothelium is principally a result
of elongation, growth, and migration of resident endothe-
lial cells (34). The present dataset is compatible with this
paradigm, showing enhanced migration of endothelial cells
from hIGFREO mice.
More recently, it has emerged that bone marrow or
other tissue-derived EPC may contribute to endothelial
repair (33). We have demonstrated that insulin-resistant
humans (35) and mice (10) have impairment of EPC mo-
bilization and function. Studies have shown that IGF-1 may
have favorable effects on EPC function and numbers in
humans (36) and mice (37). Our dataset demonstrating the
expression of the human IGF-1R in EPC from hIGFREO
mice but not wild type and the enhanced endothelium re-
pair after injury raises the possibility that increasing IGF-
1R expression may have an effect on EPC function, and
this warrants further studies.
Perspective. In the present dataset and our recent report
(15), we have demonstrated that within a tight and physi-
ologically relevant range, the IGF-1R plays a critical role in
regulating basal NO bioavailability and insulin-mediated
NO release. We have also shown a novel role for the IGF-1R
in regulation of nNOS and that the effect of the IGF-1R ap-
pears to be speciﬁc to insulin-mediated NO release.
Despite leading to reduced basal and insulin-stimulated
NO release, increasing IGF-1R enhances endothelial repair.
This provides a compelling portfolio of evidence supporting
an important role for IGF-1R within a (patho)physiological
range in regulating NO bioavailability and vascular repair.
Many human diseases are characterized by excessive or
impaired tissue growth and vascularization. The present
dataset and our previous report (15) establish the manipu-
lation of IGF-1R: insulin receptor stoichiometry as a novel
approach to regulating NO bioavailability and a potential
treatment for disorders of excessive or impaired vascular
growth and repair. Examining how hybrid formation is
regulated and whether or not the human IGF-1R behaves
differently to mouse IGF-1R in hybrid formation warrant
future work.
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